On December 25, the National Medical Products Administration (NMPA) approved the clinical trial application for the freeze-dried shingles virus mRNA vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of SINOVAC Kexing. This vaccine can stimulate the body to produce immunity against the shingles virus and is intended for the prevention of shingles in individuals aged 40 and older.
SINOVAC科兴冻干带状疱疹病毒mRNA疫苗获批临床
The SINOVAC Kexing freeze-dried shingles virus mRNA vaccine has been approved for clinical use.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated